ASCO GU 2024: Adjuvant Pembrolizumab Improves Survival in Patients With Kidney Cancer
Survival benefit seen across a variety of patient subgroups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.